{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-26-000003","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2026-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.009292+00:00","generated_at":"2026-05-16T11:04:36.835523+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Zentalis updates azenosertib program; DENALI Part 2 topline readout expected by year-end 2026","bullets":["Completed enrollment in DENALI Part 2a, supporting registration-intended development of azenosertib.","Aligned with FDA on confirmatory ASPENOVA Phase 3 trial design for Cyclin E1-positive PROC.","Cash, equivalents and securities of $280.7M as of Sep 30, 2025; runway into late 2027.","2026 milestones: Part 2a dose confirmation H1, ASPENOVA initiation H1, Part 2 topline by YE.","DENALI Part 2, if successful, could support accelerated approval for azenosertib in PROC."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-26-000003","json":"https://secwatch.observer/filing/0001725160-26-000003.json","markdown":"https://secwatch.observer/filing/0001725160-26-000003.md","text":"https://secwatch.observer/filing/0001725160-26-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000003/0001725160-26-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000003/zntl-20260106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:04:36.835523+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}